市场调查报告书
商品编码
1359574
心内膜心肌切片市场规模 - 按产品(镊子、配件)、按尖端(大弯、直、预弯)、最终用途和 - 到 2032 年的全球预测Endomyocardial Biopsy Market Size - By Product (Forceps, Accessories), By Tip (Maxi-curved, Straight, Pre-curved), By End-use & - Global Forecast to 2032 |
由于心臟相关疾病(包括心肌病变和心臟移植监测)的盛行率上升,以及对诊断和监测工具的更高需求,预计2023 年至2032 年心内膜心肌活检市场规模将以6.8% 的复合年成长率扩大。
最近,患者越来越意识到心臟评估(包括心内膜心肌切片)的重要性。医生也认识到早期检测和精确监测心臟病的价值,进一步推动了心内膜心肌活检的推荐和处方。此外,独立的临床实验室平台正在增强其诊断测试能力和服务以支持市场发展。举个例子,2023年9月,大型独立临床实验室公司艾迪康控股有限公司开始提供中国领先的精准肿瘤公司Guardant Health的液体活检测试,以加速创新癌症疗法的临床研发。
整个心内膜心肌切片市场按产品、尖端、最终用途和地区进行细分。
根据产品,配件领域的产业价值预计在 2023 年至 2032 年间获得显着增长。心内膜心肌活检手术严重依赖专用配件,如活检钳、导管和针头。心血管疾病发生率的增加推动了对这些关键工具的持续需求,进一步需要准确的诊断和监测。活检配件的技术进步,例如改进设计和材料以提高安全性和精度也将刺激该细分市场的成长。
就最终用途而言,门诊手术中心(ASC) 细分市场将在2022 年为心内膜心肌活检行业带来可观的收入,预计到2032 年将出现大幅增长。这是由于人们越来越偏爱心臟手术,包括心内膜心肌活检。ASC 具有成本效益、便利性和患者住院时间较短等特点。由于对提供门诊护理的日益关注,心内膜心肌活检微创技术的不断进步将有助于该领域的扩张。
由于心血管疾病盛行率上升(主要在印度和中国),亚太地区心内膜心肌切片市场预计在 2023 年至 2032 年间将出现强劲成长。意识的提高、医疗保健基础设施的改善以及先进诊断程序的普及正在推动对心内膜心肌活检的需求。据估计,到2060年,亚洲65岁及以上的人口将超过12亿人。该地区不断增长的老年人口可能会导致心臟评估和监测需求的增加,从而进一步推动该地区行业的成长。
Endomyocardial Biopsy Market size is anticipated to expand at 6.8% CAGR from 2023 to 2032 driven by the rising prevalence of heart-related conditions, including cardiomyopathies and heart transplant monitoring coupled with the higher need for diagnostic and monitoring tools.
Lately, patients have grown increasingly aware about the significance of cardiac assessments, including endomyocardial biopsies. Physicians are also recognizing the value of early detection and precise monitoring of heart conditions, further fueling the recommendation and prescription of endomyocardial biopsies. Moreover, independent clinical laboratory platforms are increasing their diagnostic testing capabilities and services to support the market development. To cite an instance, in September 2023, Adicon Holdings Limited, a major independent clinical laboratory firm, started providing liquid biopsy tests from Guardant Health, a leading precision oncology company, in China to accelerate clinical R&D of innovative cancer therapeutics.
The overall endomyocardial biopsy market is segmented in terms of product, tip, end-use, and region.
Based on product, the industry value from the accessories segment is poised to gain significant traction between 2023 and 2032. Endomyocardial biopsy procedures rely heavily on specialized accessories, such as biopsy forceps, catheters, and needles. The continuous demand for these critical tools is driven by the increasing incidence of cardiovascular diseases, further necessitating accurate diagnosis and monitoring. Technological advancements in biopsy accessories, such as improved design and materials for enhanced safety and precision will also stimulate the segment growth.
In terms of end-use, the ambulatory surgical centers (ASCs) segment generated considerable revenue in the endomyocardial biopsy industry in 2022 and is projected to witness substantial growth through 2032. This is owing to the increasing preference for cardiac procedures, including endomyocardial biopsies at ASCs due to their cost-effectiveness, convenience, and shorter patient stays. The rising advancements in minimally invasive techniques for endomyocardial biopsies driven by the surging focus on providing outpatient care will contribute to the segment expansion.
Asia Pacific endomyocardial biopsy market is slated to record robust growth between 2023 and 2032 attributed to the rising prevalence of cardiovascular diseases, mainly in India and China. Increasing awareness, improved healthcare infrastructure, and greater access to advanced diagnostic procedures are driving the demand for endomyocardial biopsies. It has been estimated that by 2060, there will be more than 1.2 billion Asians aged 65 years and above. This growing geriatric population in the region may contribute to the increased need for cardiac assessment and monitoring, further propelling the regional industry growth.